EZH2 and glioblastoma: GBM cells are capable of experiencing molecular subtype transitions under the influence of a diverse tumor milieu resulting in diverse consequences between the in vitro and in vivo experiments by BMI1 and EZH2 inhibitor administration (Table 1) [74].